For example, increased R‐loop formation is observed in spliceosome mutant leukemias and this has been shown to sensitize them to ATR inhibition.147 Moreover, unbiased genetic and chemical screening approaches in the context of spliceosome mutant cancers will be crucial for uncovering novel biological features, as well as uncovering therapeutically actionable targets. This evidence concerns the gene ATR and leukemia.